PRA Health Sciences Opens New Bioanalytical Laboratory in the Netherlands
PRA Health Sciences (PRA) (NASDQ: PRAH) is pleased to announce the opening of its brand new, state-of-the-art Bioanalytical Laboratory in Assen, the Netherlands. The 33,000 square foot facility provides 25 percent more space than PRA’s previous lab, includes investments in the newest small and large molecule equipment, and allows for optimal bioanalytical process efficiencies. The new laboratory is also located close to PRA’s Phase I clinics in Groningen and Zuidlaren, providing easy access and analysis of the most time-critical samples and execution of adaptive trials.
“We are proud to offer our clients industry-leading, high quality, high science laboratory services in this new and innovative environment,” said Peter Ketelaar, PRA Vice President of Global Bioanalytical Laboratory Services. “The new facility is a testament to PRA’s commitment to excellence and our passion to advance clinical development.”
PRA bioanalytical laboratories have 30+ years of experience in providing bioanalytical services in support of clinical and pre-clinical trials for both small and large molecules. Industry leading experts with a depth of scientific and regulatory knowledge and experience manage and support PRA’s laboratory services, contributing to successful development of new medicines.
“Our technology investments and innovative services operations are what set PRA apart in the industry,” said PRA CEO Colin Shannon. “We take enormous pride in the expertise we bring to the table that enables us to excel at clinical research and deliver quality results for our clients and patients.”
PRA operates GLP-compliant (Good Laboratory Practice) and fully harmonized bioanalytical laboratories in the Netherlands and the Unites States (Lenexa, Kansas). Both are strategically located near PRA’s clinical research units to enable close collaboration and faster drug development decision making.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
